Astellas adds two senior executives at US site
pharmafile | December 5, 2011 | Appointment | Business Services, Manufacturing and Production, Sales and Marketing | Astellas
Astellas’ US subsidiary Agensys has appointed Frank Hudson as vice president of finance, and Wolfgang Noe as vice president of process sciences and manufacturing.
Agensys is the company’s centre of antibody product discovery and development operations, and was acquired by Astellas in 2007.
Hudson joins Agensys from the Mannkind Corporation where he served as vice president of finance since 2007.
In his new role Hudson will be responsible for finance, procurement and information technology.
Noe joins Agensys from Biogen, where he most recently served as vice president of strategic development and technical alliances.
As vice president of operations and process sciences at Agensys, Noe will be responsible for manufacturing development and manufacturing of clinical and pre-clinical drug supplies.
Related Content

Astellas and Elpiscience enter collaboration for novel bispecific macrophage engager
Elpiscience Biopharma and Astellas Pharma have announced that they have entered into a research collaboration …

EMA accepts Astellas’ MAA for Zolbetuximab
Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted the company’s marketing …

Astellas and Cullgen enter into $1.9bn strategic collaboration to progress protein degraders
Japanese pharmaceutical company Astellas and US-based clinical-stage biopharmaceutical company Cullgen have announced that they have …






